Micro Therapeutics Inc., an Irvine-based medical device company, posted improved financial results in the second quarter.
The company, which makes devices to treat neurovascular disease, saw its net loss narrow to $2.2 million in the quarter ended July 3, versus a loss of $4.1 million a year earlier.
Sales increased 44% to $13.1 million as it expanded the number of products it sold and boosted its international distribution.
Last month the Food and Drug Administration cleared its Onyx system for treating diseased blood vessels in the brain. Micro Therapeutics said it planned to start selling Onyx, which has been available internationally since 2002, immediately in the U.S.
Micro Therapeutics shares were unchanged at $6.15 in after-hours trading.
Meanwhile, ev3 Inc., a Minnesota-based company that owns a majority stake in Micro Therapeutics, posted a net loss of $40.9 million in the quarter, up from a loss of $32.8 million a year ago.
Ev3’s sales rose to $31.5 million from $20.6 million last year.
